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Abstract
Objectives: Increasingly, medical research involves patients who complete outcomes in different languages. This occurs in
countries with more than one common language, such as Canada (French/English) or the United States (Spanish/English), as
well as in international multi-centre collaborations, which are utilized frequently in rare diseases such as systemic sclerosis
(SSc). In order to pool or compare outcomes, instruments should be measurement equivalent (invariant) across cultural or
linguistic groups. This study provides an example of how to assess cross-language measurement equivalence by comparing
the Center for Epidemiologic Studies Depression (CES-D) scale between English-speaking Canadian and Dutch SSc patients.
Methods: The CES-D was completed by 922 English-speaking Canadian and 213 Dutch SSc patients. Confirmatory factor
analysis (CFA) was used to assess the factor structure in both samples. The Multiple-Indicator Multiple-Cause (MIMIC) model
was utilized to assess the amount of differential item functioning (DIF).
Results: A two-factor model (positive and negative affect) showed excellent fit in both samples. Statistically significant, but
small-magnitude, DIF was found for 3 of 20 items on the CES-D. The English-speaking Canadian sample endorsed more
feeling-related symptoms, whereas the Dutch sample endorsed more somatic/retarded activity symptoms. The overall
estimate in depression scores between English and Dutch was not influenced substantively by DIF.
Conclusions: CES-D scores from English-speaking Canadian and Dutch SSc patients can be compared and pooled without
concern that measurement differences may substantively influence results. The importance of assessing cross-language
measurement equivalence in rheumatology studies prior to pooling outcomes obtained in different languages should be
emphasized.
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Introduction
Health-related patient-reported outcome (HR-PRO) measures
assess patient health, well-being, and response to treatment based
on patient perspectives. They may reflect complex constructs, such
as health-related quality of life, or narrower constructs, such as
individual symptoms (e.g., pain or fatigue) that are used to assess
health status in patients with rheumatic diseases [1–4]. Growing
recognition of the importance of HR-PROs and their increasing
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integration into both research and clinical practice has led to
initiatives to improve their operationalization.
In the rheumatic diseases, OMERACT (Outcome Measures in
Rheumatology) [5] has delineated a set of standards by which
measures can be evaluated, including the truth or validity,
discrimination, and feasibility of measures. Recently, the COS-
MIN checklist (Consensus-based Standards for the selection of
health status Measurement Instruments) [6] was developed to
establish criteria for evaluating the methodological quality of
studies on HR-PROs. In addition to the standards described by
OMERACT, the COSMIN checklist emphasizes the importance
of establishing the cross-cultural validity of HR-PROs.
The cross-cultural validity of HR-PROs is increasingly impor-
tant in medical research, since patients who complete outcome
measures in different languages are commonly included in the
same study. For instance, this often occurs in countries with more
than one highly common language, such as Canada (French/
English) or the United States (Spanish/English). In addition,
multicenter trials that include centres from different countries are
increasingly frequent. Particularly in rare diseases, such as systemic
sclerosis (SSc), effective research often requires international
collaboration to include a sufficient number of patients for
adequately powered studies. The Scleroderma Clinical Trials
Consortium [7] and the EULAR Scleroderma Trials and
Research group [8], for instance, routinely conduct multicentre
drug trials involving patients from multiple countries and measures
translated into multiple languages. Recently, the Scleroderma
Patient-centered Intervention Network was organized to test
psychosocial and rehabilitation interventions in patients from
across Europe and North America [9].
As described in the COSMIN checklist [6], it is important to
assess the degree to which outcome measures generate scores that
are equivalent or invariant across linguistic or cultural groups,
meaning that individuals from different groups with similar levels
of an outcome of interest should obtain equal scores on the
measure and respond similarly to individual items of the measure.
This is because differences in the meaning of items due to
translation or cultural differences in item interpretation can lead to
responses that differ across groups even when levels of the outcome
being measured are similar. Measurement differences between
translated questionnaires can be a serious threat to the validity of
cross-cultural comparisons, because when measures are not
equivalent metrically, it is not possible to determine if any
observed differences between groups reflect real differences or are
a consequence of measurement artifacts (e.g., linguistic/cultural
differences) [10]. Therefore, cross-cultural validity should be
established if HR-PROs are to be pooled among study participants
from different countries or used to compare results between
patients from different cultural or linguistic groups [11].
Differential item functioning (DIF) is said to occur when an item
of a HR-PRO has different measurement properties for one group
compared to another, irrespective of true differences of the
construct measured. Diverse statistical methods for assessing the
presence of DIF are available, based on non-parametric,
parametric or latent variable models, each with its own advantages
and disadvantages [12]. Generally, however, the presence of DIF
is assessed by identifying differences in individual item scores
across groups that are present even after controlling for levels of
the overall construct being measured. When DIF is identified, it is
assumed that scores on the item are influenced by group
characteristics that are not directly related to the construct being
measured. When translated versions of HR-PROs are adminis-
tered in different cultural settings, DIF may occur because of
alterations in item meaning due to translation or because of
cultural factors that influence interpretation of item meaning.
HR-PRO measures for depressive symptoms are increasingly
used among patients with chronic medical illness [13,14]. This is
also the case for patients with SSc, which is an autoimmune
disease characterized by thickening of the skin as a result of
fibrosis, as well as involvement of multiple internal organs, most
commonly the lungs, gastrointestinal tract and heart [15]. In SSc,
the Center for Epidemiologic Studies Depression Scale (CES-D)
[16] has been used to assess depressive symptoms in English [17–
20], French [19,20], Dutch [21], and German [22]. The CES-D
was originally developed in the USA to measure depressive
symptomatology in the general population [16]. The scale has also
shown to be a reliable and valid measure of depressive symptoms
across various patient samples, including SSc [23]. No studies,
however, in any patient group have assessed the degree to which
translated versions of the CES-D are measurement equivalent
versus exhibiting substantive DIF, possibly due to the unfamiliarity
of researchers and clinicians with the need for assessment of cross-
language measurement properties or the methods by which this
can be done. This study provides an example of how to assess
cross-language measurement equivalence by comparing the CES-
D between English-speaking Canadian and Dutch SSc patients.
Methods
Ethics Statement
The English-speaking sample of this cross-sectional study
consisted of patients with SSc enrolled in the Canadian
Scleroderma Research Group Registry (CSRG). The study was
approved by the Institutional Review Board of McGill University.
The Dutch sample consisted of patients with SSc enrolled in a 3-
year cohort study in Nijmegen, The Netherlands. The study was
approved by the Institutional Review Board of the Radboud
University Medical Center Nijmegen (CMO2008/109). All
patients provided written consent for their information to be
stored in a computer database and used for research.
Patients and Procedures
English-speaking sample. The English-speaking sample
consisted of patients enrolled in the CSRG who completed the
CES-D in English from September 2004 through April 2011.
Patients in the Registry are recruited from 15 centers across
Canada. To be eligible for the Registry, patients must have a
diagnosis of SSc confirmed by a Registry rheumatologist, be 18
years of age, and be fluent in English or French. Registry patients
undergo extensive physical evaluation at annual visits and
complete a series of self-report questionnaires in their preferred
language (English or French). For patients who completed the
CES-D at multiple annual visits, only data from the most recent
visit was included in analyses in the present study.
Dutch sample. The Dutch sample consisted of SSc patients
treated at the Sint Maartenskliniek or Radboud University
Medical Center Nijmegen, The Netherlands who completed the
baseline assessment of a 3-year cohort study, including the CES-D
in Dutch, between June 2008 and February 2010. To be eligible,
patients had to have a diagnosis of SSc according to the
preliminary American College of Rheumatology classification
criteria [24]. Exclusion criteria for participation in the cohort were
a life expectancy ,1 year, acute serious complications (e.g., renal
crisis), severe psychiatric co-morbidity, other serious co-morbidi-
ties (e.g., cancer) and insufficient knowledge of the Dutch
language.
Measurement Equivalence of the CES-D
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Measures
Demographics and disease characteristics. Demographic
variables for both samples included age, sex, marital status,
education and current employment status. Disease characteristics
were assessed by study rheumatologists in both samples, including
disease duration, SSc subtype, and the modified Rodnan skin
score (mRSS). Disease duration was defined as time since onset
from first non-Raynaud symptom. Patients were classified as
having limited or diffuse SSc. Limited SSc was defined as skin
involvement distal to the elbows and knees only, whereas diffuse
SSc was defined as skin involvement proximal to the elbows and
knees, and the trunk also [25]. The mRSS is a standardized rating
of skin involvement ranging from 0 (no involvement) to 3 (severe
thickening) in 17 body areas (total score range 0–51) [26].
Symptoms of depression. The CES-D [16] is a 20-item
measure that assesses the frequency of symptoms during the past
week on a 0–3 Likert scale (‘‘rarely or none of the time’’ to ‘‘most
or all of the time’’). Standard cutoffs are $16 for ‘‘possible
depression’’ and $23 for ‘‘probable depression’’ [16]. A cutoff of
$19 has been suggested in arthritis [27]. The CES-D used in the
English-speaking sample was the original version [16], which has
shown to be a reliable and valid measure of depressive symptoms
in patients with SSc [23]. In the Dutch sample, the original
translation [28], which has been shown to be reliable and valid
across diverse settings was used.
Statistical Analyses
Demographics and disease characteristics were compared
between the English-speaking and Dutch samples using the chi-
square statistic for categorical variables and t-tests for continuous
variables.
A flowchart of steps undertaken in the DIF analysis is depicted
in Figure 1. First, the factor structure of the CES-D was assessed
for each sample separately using confirmatory factor analysis
(CFA). Ideally for DIF assessment, the simplest structure with
reasonable fit will be used. Thus, an initial CFA model was
constructed with Mplus [29] to determine if a single-dimensional
structure of the CES-D in SSc could be reasonably used in the DIF
analysis versus an alternative structure. Selection of an alternative
structure was based on a previous validation study of the CES-D in
SSc [23]. Item responses for the CES-D were ordinal Likert data,
so the weighted least squares estimator with a diagonal weight
matrix, robust standard errors, and a mean- and variance-adjusted
chi-square statistic was used with delta parameterization [29].
Modification indices were used to identify pairs of items within
scales for which model fit would improve if error estimates were
freed to covary and for which there appeared to be theoretically
justifiable shared method effects (e.g., similar wording) [30]. To
assess model fit, the chi-square test, the Tucker-Lewis Index (TLI)
[31], the Comparative Fit Index (CFI) [32] and the Root Mean
Square Error of Approximation (RMSEA) [33] were used. Since
the chi-square test is highly sensitive to sample size, it can lead to
the rejection of well-fitting models [34]. Therefore, the TLI, CFI
and RMSEA fit indices were emphasized. Good fitting models are
indicated by a TLI and CFI$0.95 and RMSEA#0.06 [35]. Once
the factor structure was established for each sample separately, a
CFA model was fit that included patients from both samples
combined.
The Multiple-Indicator Multiple-Cause (MIMIC) model was
utilized to determine if items of the CES-D exhibited DIF for
English-speaking versus Dutch patients. MIMIC models for DIF
assessment are based on structural equation models, in which the
group variable (English/Dutch) is added to the basic CFA model
as an observed variable. Thus, the base MIMIC model consists of
the CFA factor model with the additional direct effect of group on
the latent factors, which serves to control for group differences on
the level of the latent factors. Since there were statistically
significant difference between our samples, we also controlled for
demographic and disease variables (age, sex, marital status,
education, current employment status, SSc subtype, mRSS and
disease duration) by adding a direct effect of these variables on the
latent factors, Then, to assess potential DIF, the direct effect of
group on CES-D items is assessed for each item separately, by
regressing the items, one at a time, on group (see Figure 2). Each
item is tested separately to determine if there is statistically
significant DIF, represented by a statistically significant link in the
model from group to the item, after controlling for any differences
in the overall level of the latent factor between groups. If there is
DIF for one or more items, the item with the largest magnitude of
DIF is considered to have DIF, and the link between the linguistic
group variable and that item is included in the model. Then, this
procedure is repeated until none of the remaining items show
significant DIF. Once all items with significant DIF are identified,
the potential magnitude of DIF items collectively, identified via
assessment of statistical significance, can be evaluated by
comparing the difference on the latent factor between groups in
the baseline CFA model and after controlling for DIF. Since the
CES-D consists of a large number of items, Hommels’ [36]
correction for multiple testing was applied. CFA and DIF analyses
were conducted using Mplus [29], all other analyses were
conducted using Stata/IC 10.1 (StataCorp LP, College Station,
TX).
Results
Sample Characteristics
Demographics and disease characteristics for both samples are
displayed in Table 1.
English-speaking sample. In total, 976 patients completed
the CES-D in English. Six patients were excluded from analysis,
because they had .2 missing values on the CES-D. Furthermore,
48 patients were excluded because they were diagnosed with sine
SSc, but not diffuse or limited SSc. Of the remaining 922 patients,
84.8% were female. Most patients (82.9%) were married or
cohabitating. The mean CES-D score was 14.3 (SD=10.3) and
the percentage of patients scoring $16 was 37.7%. The
percentage of patients with CES-D$19 was 28.7%.
Dutch sample. In total, 215 patients completed the baseline
questionnaires. Two patients were excluded from the analysis
because they had .2 missing values on the CES-D. Of the 213
patients in the sample, 67.6% were female. Most patients (75.6%)
were married or cohabitating. The mean CES-D score was 12.8
(SD=9.6) and the percentage of patients scoring $16 was 31.9%.
The percentage of patients with CES-D$19 was 24.9%.
Compared with the English-speaking sample, patients in the
Dutch sample were significantly more likely to be male and to
have limited disease. They were less likely to have completed more
than 12 years of education, or to be currently working.
Furthermore, patients in the Dutch sample had significantly
shorter disease duration and lower mean mRSS scores. Mean
CES-D scores in the Dutch sample were somewhat lower than in
the English-speaking sample (P = 0.05). The proportion of patients
with CES-D$16 (P= 0.11) and CES-D $19 (P= 0.27) did not
differ significantly.
Confirmatory Factor Analysis
For both samples, a single-factor structure was assessed initially.
In both the English-speaking and Dutch samples, the fit was poor
Measurement Equivalence of the CES-D
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(English-speaking: x2(76) = 2218.8, P,0.001, CFI = 0.71,
TLI = 0.88, RMSEA=0.18; Dutch: x2(50) = 259.0, P,0.001,
CFI = 0.87, TLI = 0.94, RMSEA=0.14). Inspection of the mod-
ification indices for both samples indicated correlated error terms
of all positively worded items (items 4, 8, 12 and 16). Since
allowing the error terms of these items to be correlated with each
other would essentially result in specifying a second factor, a two-
factor model was refitted, with two correlated factors: positive and
negative [27]. The two-factor model showed good fit to the data in
both samples (English-speaking: x2(81) = 572.6, P,0.001,
CFI = 0.93, TLI= 0.98, RMSEA=0.08; Dutch: x2(51) = 128.3,
P,0.001, CFI= 0.95, TLI = 0.98, RMSEA=0.08). In both
samples, inspection of modification indices indicated that freeing
error terms to covary for items 15 and 19, 17 and 18, and 7 and
20, would improve model fit, and in each case there was clearly
recognizable overlap in the items’ content. Therefore, the model
was refitted to the data, allowing the error terms for those items to
be correlated. This change resulted in a model with excellent fit to
the data in both samples (English-speaking: x2(81) = 345.1,
P,0.0001, CFI= 0.96, TLI= 0.99, RMSEA=0.06; Dutch:
x2(51) = 94.6, P,0.0001, CFI= 0.97, TLI= 0.99,
RMSEA=0.06).
Differential Item Functioning
The two-factor model that was fit for each sample individually
was fit with all patients in the same model (Table 2), along with a
direct effect of group (English/Dutch) on both factors (‘‘positive’’/
‘‘negative’’). As shown in Table 3, model fit for the combined
sample for this base model was excellent. Prior to accounting for
DIF, English-speaking patients had higher latent factor scores than
Dutch patients: 0.19 standard deviations for ‘‘positive’’ factor
scores, and 0.03 standard deviations for ‘‘negative’’ factor scores,
Figure 1. Flowchart of steps to be undertaken in DIF analysis.
doi:10.1371/journal.pone.0053923.g001
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although neither difference was statistically significant. Initially,
three items showed significant DIF: items 3, 4, and 7. Item 3
(z = 4.4, P,0.001) and item 4 (z = 4.4, P,0.001) had higher scores
in the English-speaking sample, controlling for differences on the
latent factors. On the other hand, item 7 (z =23.6, P,0.001) had
higher scores in the Dutch sample. All three items continued
showing DIF, throughout the sequence of correcting for DIF on
the other items.
After correcting for DIF, compared to the base model, there was
a decrease of 0.10 standard deviations on the ‘‘positive’’ latent
factor and a decrease of 0.01 standard deviations on the
‘‘negative’’ latent factors in the difference between English-
speaking and Dutch patients, and confidence intervals were
overlapping, as shown in Table 3. Thus, although there was
statistically significant DIF on three CES-D items, this did not
influence the overall estimates of depression latent factor scores
between English-speaking and Dutch patients substantively.
Discussion
In order to compare or pool data obtained with HR-
PRO measures that are administered in different languages,
cross-cultural or cross-linguistic equivalence of scores should be
established. As an example of how to conduct such type of studies,
in the present study the cross-linguistic measurement equivalence
was assessed for the CES-D in English-speaking Canadian and
Dutch SSc patients. Significant DIF was found for 3 of 20 items on
the CES-D. However, the magnitude of DIF for each of these
items was very small, and the effect on overall CES-D scores was
negligible. This means that if there is DIF, it is so small that CES-
D scores would not be influenced meaningfully by it.
Small-magnitude DIF was found for some items in our study.
DIF in cross-linguistic comparisons may be caused by a lack of
conceptual equivalence due to differences in content, format,
difficulty or cultural relevance for the English-speaking compared
to the Dutch sample [10]. The Dutch sample scored higher, even
after controlling for latent depression symptom levels, on 2 items
that were similar in meaning and related to energy levels and
Figure 2. The MIMIC Model for the Centre for Epidemiologic Studies Depression Scale (CES-D).
doi:10.1371/journal.pone.0053923.g002
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effort. Canadian English-speaking patients, on the other hand,
appeared to endorse more ‘feeling’ symptoms. It is possible that
this is related to cultural differences in how symptoms are
experienced or expressed. It is also possible, however, that these
differences may be related to translation. For item 7 (‘‘Effort’’), no
remarkable differences were found in the translations. This was
not the case, however, for items 3 (‘‘Blues’’) and 4 (‘‘Good’’). In
fact, there are many examples of discussions in the published
literature related to the difficulty of translating from English
‘‘feeling blue’’ and related expressions such as ‘‘having the blues’’
[37–39]. In many languages, including Dutch, a strictly lexical
translation for these terms is meaningless. Therefore, in translated
versions, words need to be found with sufficient similarity to
convey the concept, which might lead to slight differences between
translated versions. For item 4 (‘‘I felt that I was just as good as
other people’’), in the Dutch version of the CES-D, the translation
Table 1. Demographic and medical characteristics for both SSc samples.
Variable English-speaking (N=922) Dutch (N=213) P value
Female (%) 782 (84.8) 144 (67.6) ,0.001
Mean age, years (SD) 55.2 (12.3)a 56.4 (12.0) 0.17
Higher education (% .12 years) 451 (49.2)b 86 (41.1)c 0.04
Currently working (%) 383 (41.7)d 70 (32.9) 0.02
Married or living as married (%) 764 (82.9) 161 (75.6) 0.01
Limited disease (%) 556 (60.3) 157 (75.1)c ,0.001
Mean disease duration (SD) 11.1 (9.3)e 9.2 (8.0)f 0.01
Mean modified Rodnan Skin Score (SD) 10.5 (9.6)g 6.4 (6.0)h ,0.001
CES-D score, mean (SD) 14.3 (10.3) 12.8 (9.6) 0.05
Due to missing values: aN = 920, bN = 918, cN = 209, dN = 919, eN= 879, fN = 206, gN= 905, hN = 207.
doi:10.1371/journal.pone.0053923.t001
Table 2. Factor loadings on the ‘‘positive’’ and ‘‘negative’’ factors of the CES-D.
Base modela DIF corrected modelb
Factor loading 95% Confidence Interval Factor loading 95% Confidence Interval
Positive factor items:
4. Good 0.57 [0.51, 0.62] 0.56 [0.50, 0.62]
8. Hopeful 0.74 [0.70, 0.78] 0.74 [0.70, 0.78]
12. Happy 0.91 [0.87, 0.95] 0.91 [0.86, 0.95]
16. Enjoy 0.83 [0.79, 0.87] 0.83 [0.79, 0.87]
Negative factor items:
1. Bothered 0.74 [0.71, 0.78] 0.74 [0.71, 0.78]
2. Appetite 0.51 [0.46, 0.57] 0.51 [0.46, 0.57]
3. Blues 0.86 [0.83, 0.89] 0.86 [0.83, 0.89]
5. Mind 0.71 [0.68, 0.76] 0.71 [0.67, 0.75]
6. Depressed 0.90 [0.88, 0.92] 0.90 [0.88, 0.92]
7. Effort 0.67 [0.63, 0.71] 0.67 [0.63, 0.71]
9. Failure 0.77 [0.72, 0.81] 0.77 [0.72, 0.81]
10. Fearful 0.68 [0.63, 0.72] 0.68 [0.63, 0.71]
11. Sleep 0.47 [0.41, 0.52] 0.47 [0.41, 0.52]
13. Talk 0.70 [0.66, 0.74] 0.70 [0.66, 0.74]
14. Lonely 0.77 [0.74, 0.81] 0.77 [0.74, 0.81]
15. Unfriendly 0.49 [0.41, 0.56] 0.49 [0.41, 0.56]
17. Cry 0.73 [0.68, 0.78] 0.73 [0.68, 0.78]
18. Sad 0.85 [0.82, 0.88] 0.85 [0.82, 0.88]
19. Dislike 0.68 [0.61, 0.74] 0.68 [0.61, 0.74]
20. Get going 0.69 [0.65, 0.73] 0.69 [0.65, 0.73]
Correlation of positive and negative latent
factors:
0.47 [0.42, 0.52] 0.47 [0.42, 0.52]
doi:10.1371/journal.pone.0053923.t002
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of ‘‘good’’ is interpreted as ‘‘worth,’’ which has a slightly different
connotation, and, therefore, might have influenced responses
differently across groups.
Despite the identification of minor DIF for several items, this
study found that CES-D scores for English and Dutch SSc patients
with equal levels of depressive symptoms would be expected to be
highly similar. In other words, possible DIF on single items was of
very small magnitude and had negligible influence on the overall
score. Therefore, scores generated with the English and Dutch
versions of the CES-D are comparable and do not require
adjustment for linguistic differences. This is an important result
given the increasingly common use of multinational collaborations
to conduct research in rare diseases, such as SSc [7–9]. Future
studies should extend the current assessment of the CES-D into
other languages. In addition, measurement equivalence should
also be assessed for other frequently used HR-PROs central to
research in rheumatic diseases, including, for instance, the Health
Assessment Questionnaire [40] and the SF-36 [41].
There are limitations that should be considered in interpreting
the results of this study. Because of the difference in sample size
between the samples, the core model used to assess DIF relied
more on data from English-speaking patients than Dutch patients.
However, since the initial factor analysis yielded the same results in
both samples, it does not seem likely that this would have
influenced results substantially. A second limitation relates to
differences in sample recruitment. Dutch patients were recruited
from two hospitals, between 2008 and 2010, whereas the English-
speaking patients were recruited from 15 centers from across
Canada between 2004 and 2011. Furthermore, there were some
differences in inclusion criteria for the two samples and in the
demographic (in particular, sex) and disease characteristics (in
particular, disease subtype and duration) of the samples. However,
the sensitivity analysis correcting for differences in demographics
and disease characteristics between samples yielded virtually the
same results as the non-corrected model, which suggests that
differences in sample characteristics did not likely influence the
results. Finally, MIMIC models do not test for non-uniform DIF.
Non-uniform DIF means that the amount of DIF is unequal for
different levels of the outcome of interest, in our case depression.
On the other hand, MIMIC models do allow for adjustment for
important covariates that may differ between comparison groups,
which is an important strength of the model.
In conclusion, there were 3 CES-D items with evidence of
minor DIF between the English and Dutch samples. Overall,
however, there was no evidence that these minor differences
influenced overall scores. Therefore, CES-D scores from English-
speaking Canadian and Dutch SSc patients can be compared and
pooled without concern that measurement differences may
substantively influence results.
Given the importance of international collaborations and multi-
center trials, in particular for research on rare diseases such as SSc,
additional studies are needed that assess the measurement of other
key HR-PROs across languages. Researchers across areas of
research and languages should be aware of the importance of
assessing cross-language measurement equivalence of HR-PROs
prior to pooling results obtained in different languages.
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